Articles By Anuja Singh
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal…
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
ByIs AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a…
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global…
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach…
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff…
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion…
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal…
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
Is AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a…
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global…
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach…
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff…
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion…
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…